Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles

INTRODUCTION: Improved therapies for glioblastoma (GBM) are desperately needed and require preclinical evaluation in models that capture tumor heterogeneity and intrinsic resistance seen in patients. Epigenetic alterations have been well documented in GBM and lysine-specific demethylase 1 (LSD1/KDM1...

Descripción completa

Detalles Bibliográficos
Autores principales: Stitzlein, Lea M., Gangadharan, Achintyan, Walsh, Leslie M., Nam, Deokhwa, Espejo, Alexsandra B., Singh, Melissa M., Patel, Kareena H., Lu, Yue, Su, Xiaoping, Ezhilarasan, Ravesanker, Gumin, Joy, Singh, Sanjay, Sulman, Erik, Lang, Frederick F., Chandra, Joya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111022/
https://www.ncbi.nlm.nih.gov/pubmed/37082446
http://dx.doi.org/10.3389/fneur.2023.1112207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111022/
https://www.ncbi.nlm.nih.gov/pubmed/37082446
http://dx.doi.org/10.3389/fneur.2023.1112207

Ejemplares similares